Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Zin W. Myint; Jill M. Kolesar; Joseph Robert McCorkle; Jianrong Wu; Carleton S. Ellis; Danielle E. Otto; Peng Wang

doi:10.12659/MSM.938091

14 October 2022 : Clinical Research

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Zin W. Myint^12ABCDEFG*, Jill M. Kolesar^23CDE, Joseph Robert McCorkle^2CDE, Jianrong Wu^4C, Carleton S. Ellis^32CDE, Danielle E. Otto^23CDE, Peng Wang^12ACDE

DOI: 10.12659/MSM.938091

Med Sci Monit 2022; 28:e938091

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 6 Logistic regression between 3-month abiraterone trough level and 3-month prostate-specific antigen ≤1 ng/mL and 7-month abiraterone trough level and 7-month prostate-specific antigen ≤0.2 ng/mL.

PSA	N	mean (tABI)a	P value

3 months
PSA ≤1	6	14.59	0.25
PSA >1	3	5.51

7 months
PSA ≤0.2	4	15.90	0.56
PSA >0.2		11.5
^a tABI, trough abiraterone; PSA – prostate-specific antigen.

Back to the Article

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Your Privacy